Literature DB >> 22892156

Cyclodextrin mediates rapid changes in lipid balance in Npc1-/- mice without carrying cholesterol through the bloodstream.

Anna M Taylor1, Bing Liu, Yelenis Mari, Benny Liu, Joyce J Repa.   

Abstract

An injection of 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) to mice lacking Niemann Pick type C (NPC) protein results in delayed neurodegeneration, decreased inflammation, and prolonged lifespan. Changes in sterol balance observed in Npc1(-/-) mice 24 h after HP-β-CD administration suggest that HP-β-CD facilitates the release of accumulated lysosomal cholesterol, the molecular hallmark of this genetic disorder. Current studies were performed to evaluate the time course of HP-β-CD effects. Within 3 h after HP-β-CD injection, decreases in cholesterol synthesis rates and increases in cholesteryl ester levels were detected in tissues of Npc1(-/-) mice. The levels of RNAs for target genes of sterol-sensing transcription factors were altered by 6 h in liver, spleen, and ileum. Despite the cholesterol-binding capacity of HP-β-CD, there was no evidence of increased cholesterol in plasma or urine of treated Npc1(-/-) mice, suggesting that HP-β-CD does not carry sterol from the lysosome into the bloodstream for ultimate urinary excretion. Similar changes in sterol balance were observed in cultured cells from Npc1(-/-) mice using HP-β-CD and sulfobutylether-β-CD, a variant that can interact with sterol but not facilitate its solubilization. Taken together, our results demonstrate that HP-β-CD works in cells of Npc1(-/-) mice by rapidly liberating lysosomal cholesterol for normal sterol processing within the cytosolic compartment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22892156      PMCID: PMC3466002          DOI: 10.1194/jlr.M028241

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  49 in total

1.  Analyzing real-time PCR data by the comparative C(T) method.

Authors:  Thomas D Schmittgen; Kenneth J Livak
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

2.  Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells.

Authors:  V M Atger; M de la Llera Moya; G W Stoudt; W V Rodrigueza; M C Phillips; G H Rothblat
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

3.  Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol.

Authors:  Hyock Joo Kwon; Lina Abi-Mosleh; Michael L Wang; Johann Deisenhofer; Joseph L Goldstein; Michael S Brown; Rodney E Infante
Journal:  Cell       Date:  2009-06-26       Impact factor: 41.582

4.  Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse.

Authors:  Benny Liu; Stephen D Turley; Dennis K Burns; Anna M Miller; Joyce J Repa; John M Dietschy
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

5.  Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells.

Authors:  Lina Abi-Mosleh; Rodney E Infante; Arun Radhakrishnan; Joseph L Goldstein; Michael S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-02       Impact factor: 11.205

6.  Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse.

Authors:  Joyce J Repa; Hao Li; Tamy C Frank-Cannon; Mark A Valasek; Stephen D Turley; Malú G Tansey; John M Dietschy
Journal:  J Neurosci       Date:  2007-12-26       Impact factor: 6.167

7.  Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1.

Authors:  David Smith; Kerri-Lee Wallom; Ian M Williams; Mylvaganam Jeyakumar; Frances M Platt
Journal:  Neurobiol Dis       Date:  2009-07-24       Impact factor: 5.996

Review 8.  Cyclodextrins.

Authors:  Valentino J Stella; Quanren He
Journal:  Toxicol Pathol       Date:  2008-01       Impact factor: 1.902

9.  Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease.

Authors:  Alejandra R Alvarez; Andrés Klein; Juan Castro; Gonzalo I Cancino; Julio Amigo; Matías Mosqueira; Lina M Vargas; L Fernanda Yévenes; Francisca C Bronfman; Silvana Zanlungo
Journal:  FASEB J       Date:  2008-06-30       Impact factor: 5.191

10.  Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.

Authors:  Cristin D Davidson; Nafeeza F Ali; Matthew C Micsenyi; Gloria Stephney; Sophie Renault; Kostantin Dobrenis; Daniel S Ory; Marie T Vanier; Steven U Walkley
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

View more
  39 in total

1.  FTY720/fingolimod increases NPC1 and NPC2 expression and reduces cholesterol and sphingolipid accumulation in Niemann-Pick type C mutant fibroblasts.

Authors:  Jason Newton; Nitai C Hait; Michael Maceyka; Alexandria Colaco; Melissa Maczis; Christopher A Wassif; Antony Cougnoux; Forbes D Porter; Sheldon Milstien; Nicholas Platt; Frances M Platt; Sarah Spiegel
Journal:  FASEB J       Date:  2017-01-12       Impact factor: 5.191

Review 2.  The potential of histone deacetylase inhibitors in Niemann - Pick type C disease.

Authors:  Michael Maceyka; Sheldon Milstien; Sarah Spiegel
Journal:  FEBS J       Date:  2013-09-23       Impact factor: 5.542

3.  Correction of Niemann-Pick type C1 trafficking and activity with the histone deacetylase inhibitor valproic acid.

Authors:  Kanagaraj Subramanian; Darren M Hutt; Samantha M Scott; Vijay Gupta; Shu Mao; William E Balch
Journal:  J Biol Chem       Date:  2020-04-30       Impact factor: 5.157

4.  Monitoring the itinerary of lysosomal cholesterol in Niemann-Pick Type C1-deficient cells after cyclodextrin treatment.

Authors:  McKenna Feltes; Sarah E Gale; Samantha Moores; Daniel S Ory; Jean E Schaffer
Journal:  J Lipid Res       Date:  2020-01-27       Impact factor: 5.922

5.  Hepatic entrapment of esterified cholesterol drives continual expansion of whole body sterol pool in lysosomal acid lipase-deficient mice.

Authors:  Amal Aqul; Adam M Lopez; Kenneth S Posey; Anna M Taylor; Joyce J Repa; Dennis K Burns; Stephen D Turley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-08-21       Impact factor: 4.052

6.  Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming.

Authors:  Sebastian Zimmer; Alena Grebe; Siril S Bakke; Niklas Bode; Bente Halvorsen; Thomas Ulas; Mona Skjelland; Dominic De Nardo; Larisa I Labzin; Anja Kerksiek; Chris Hempel; Michael T Heneka; Victoria Hawxhurst; Michael L Fitzgerald; Jonel Trebicka; Ingemar Björkhem; Jan-Åke Gustafsson; Marit Westerterp; Alan R Tall; Samuel D Wright; Terje Espevik; Joachim L Schultze; Georg Nickenig; Dieter Lütjohann; Eicke Latz
Journal:  Sci Transl Med       Date:  2016-04-06       Impact factor: 17.956

7.  Systemic administration of 2-hydroxypropyl-β-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function.

Authors:  Adam M Lopez; Sandi J Terpack; Kenneth S Posey; Benny Liu; Charina M Ramirez; Stephen D Turley
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-10       Impact factor: 2.557

8.  Cyclodextrin alleviates neuronal storage of cholesterol in Niemann-Pick C disease without evidence of detectable blood-brain barrier permeability.

Authors:  Charles C Pontikis; Cristin D Davidson; Steven U Walkley; Frances M Platt; David J Begley
Journal:  J Inherit Metab Dis       Date:  2013-02-15       Impact factor: 4.982

9.  Niemann-Pick C1-deficient mice lacking sterol O-acyltransferase 2 have less hepatic cholesterol entrapment and improved liver function.

Authors:  Adam M Lopez; Ryan D Jones; Joyce J Repa; Stephen D Turley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-06-07       Impact factor: 4.052

10.  PRD125, a potent and selective inhibitor of sterol O-acyltransferase 2 markedly reduces hepatic cholesteryl ester accumulation and improves liver function in lysosomal acid lipase-deficient mice.

Authors:  Adam M Lopez; Jen-Chieh Chuang; Kenneth S Posey; Taichi Ohshiro; Hiroshi Tomoda; Lawrence L Rudel; Stephen D Turley
Journal:  J Pharmacol Exp Ther       Date:  2015-08-17       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.